Johannes Rosenbrock

University Hospital Cologne, University of Cologne

Papers

Total Citations

H-Index

About

Johannes Rosenbrock is a health outcomes researcher whose work sits at the intersection of advanced medical technology and economic evaluation, with a focus on oncology. His primary research areas include cost-utility analysis for novel cancer therapies, focal treatments for prostate cancer, and stereotactic body radiotherapy (SBRT) for oligometastatic disease. Rosenbrock’s major contribution is the rigorous assessment of emerging, less-invasive treatments—quantifying not just their clinical efficacy but their real-world value. His most cited work, a 2025 cost-utility analysis of MR-guided transurethral ultrasound ablation (MR-TULSA) for low- to intermediate-risk localized prostate cancer, provides critical evidence that this focal therapy may offer a favorable balance of reduced adverse effects and cost-effectiveness compared to established treatments. This study, with 3 citations, is foundational for supporting large-scale clinical implementation of MR-TULSA. Additionally, his 2023 investigation into robotic SBRT for lung metastases (2 citations) identifies key factors determining treatment success in oligometastatic patients. Through these analyses, Rosenbrock is helping to shape value-based decision-making in oncology, making him a notable voice in the push toward personalized, economically sustainable cancer care.